CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.
Journal Information
Full Title: J Transl Med
Abbreviation: J Transl Med
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsC.D. is co-founder of Orbits® Oncology, an image and data analysis platform that was used in this study. Competing interests C.D. is co-founder of Orbits® Oncology, an image and data analysis platform that was used in this study."
Funding Disclosure
Evidence found in paper:
"Funding This project was founded by FWO (Research Foundation Flanders)—"Kom op tegen kanker". Project number: G094820N."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025